Pharmaceutical foams: are they the answer to the dilemma of topical nanoparticles?

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 6, Issue 2, 2010, Pages 227-236

  Zhao, Yanjun ^a   Brown, Marc B ^b,c   Jones, Stuart A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MEDPHARM LTD   (United Kingdom)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Dynamic; Foam; Nanoparticle; Topical; Vehicle

Indexed keywords

ACTIVE AGENTS; BREAK DOWN; CURRENT STATUS; DELIVERY SYSTEMS; DRUG LOADING; DRUG RELEASE; DYNAMIC SYSTEMS; FOAM PRODUCTION; NANOPARTICULATE SYSTEM; SCIENTIFIC ADVANCES; SKIN PENETRATION; THERAPEUTIC AGENTS; TOPICAL; TOPICAL DRUGS; TOPICAL VEHICLE;

DISSOLUTION; DRUG DELIVERY; DRUG DOSAGE; DYNAMIC PROGRAMMING; DYNAMICAL SYSTEMS;

NANOPARTICLES;

ALCOHOL DERIVATIVE; ALOE VERA EXTRACT; ANESTAFOAM; BACTOSHIELD; BETAMETHASONE VALERATE; CHLORHEXIDINE GLUCONATE; CLENIA; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; CLOBETASOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; EXTINA; FLAVONOID; HYDRO 40 FOAM; HYDROCORTISONE; HYDROCORTISONE ACETATE; IBULEVE; IBUPROFEN; KERAFOAM; KERATOLYTIC AGENT; KETOCONAZOLE; LIDOCAINE; LUXIQ; MENTHOL; MINOXIDIL; NONOXINOL 9; OLUX E; OVACE; PIPERONYL BUTOXIDE; PRAMOCAINE; PROCTOFOAM; PYRETHRIN; SALICYLIC ACID; SALKERA; SELENIUM SULFIDE; SULFACETAMIDE; SULFUR; TERSI FOAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; VERDESO; VITAMIN; VITAMIN D DERIVATIVE;

ACNE; ACNE VULGARIS; BURN; CALLUS; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CLINICAL TRIAL; CREAM; DERMATITIS; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG PENETRATION; DRUG POTENTIATION; DRUG PREFERENCE; DRUG RELEASE; DRUG RESEARCH; DRY SKIN; FOAM; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; MUSCULOSKELETAL PAIN; OINTMENT; PAIN; PATIENT COMPLIANCE; PEDICULOSIS; PHARMACEUTICAL FOAM; PRODUCT DEVELOPMENT; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; REVIEW; ROSACEA; SEBORRHEA; SEBORRHEIC DERMATITIS; SKIN INFLAMMATION; SKIN PERMEABILITY; TINEA VERSICOLOR; TOPICAL TREATMENT; VERRUCA VULGARIS; XERODERMA;

ADMINISTRATION, TOPICAL; DRUG CARRIERS; DRUG COMPOUNDING; GASES; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS;

EID: 77949912024     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2009.08.002     Document Type: Review

References (86)

1. Souto E.B., and Muller R.H. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci 30 (2008) 157-165
2. Dingler A., Blum R.P., Niehus H., Muller R.H., and Gohla S. Solid lipid nanoparticles (SLN™/Lipopearls™)-a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul 16 (1999) 751-767
3. Jenning V., and Gohla S.H. Encapsulation of retinoids in solid lipid nanoparticles (SLN (R)). J Microencapsul 8 (2001) 149-158
4. Wissing S.A., Muller R.H., Manthei L., and Mayer C. Structural characterization of Q10-loaded solid lipid nanoparticles by NMR spectroscopy. Pharm Res 21 (2004) 400-405
5. Puglia C., Blasi P., Rizza L., Schoubben A., Bonina F., Rossi C., et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm 357 (2008) 295-304
6. Jenning V., Schafer-Korting M., and Gohla S.H. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 66 (2000) 115-126
7. Cui Z., and Mumper R.J. Chitosan-based nanoparticles for topical genetic immunization. J Control Release 75 (2001) 409-419
8. Friedman A.J., Phan J., Tang D., Oren A., Modlin R., and Kim J. Chitosan nanoparticles: agent for topical treatment of cutaneous inflammatory and infectious diseases. J Invest Dermatol 127 (2007) S130
9. Shim J., Kang H., Park W.S., Han S.H., Kim J., and Chang I.S. Transdermal delivery of minoxidil with block copolymer nanoparticles. J Control Release 97 (2004) 477-484
10. Alvarez-Roman R., Naik A., Kalia Y.N., Guy R.H., and Fessi H. Skin penetration and distribution of polymeric nanoparticles. J Control Release 99 (2004) 53-62
11. Schafer-Korting M., Mehnert W., and Korting H.C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 59 (2007) 427-443
12. Muller R.H., Radtke M., and Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54 (2002) S131-S155
13. Alvarez-Roman R., Naik A., Kalia Y.N., Guy R.H., and Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res 21 (2004) 1818-1825
14. Stracke F., Weiss B., Lehr C.M., Koenig K., Schaefer U.F., and Schneider M. Multiphoton microscopy for the investigation of dermal penetration of nanoparticle-borne drugs. J Invest Dermatol 126 (2006) 2224-2233
15. Zhao Y., Brown M.B., and Jones S.A. Engineering novel topical foams using hydrofluroalkane emulsions stabilised with pluronic surfactants. Eur J Pharm Sci 37 (2009) 370-377
16. Zhao Y., Moddaresi M., Jones S.A., and Brown M.B. A dynamic topical hydrofluoroalkane foam to induce nanoparticle modification and drug release in situ. Eur J Pharm Biopharm 72 (2009) 521-528
17. Purdon C.H., Haigh J.M., Surber C., and Smith E.W. Foam drug delivery in dermatology: beyond the scalp. Am J Drug Deliv 1 (2003) 71-75
18. Tamarkin D., Friedman D., and Shemer A. Emollient foam in topical drug delivery. Expert Opin Drug Deliv 3 (2006) 799-807
19. Pilpel N. Foams in pharmacy. Endeavour 9 (1985) 87-91
20. Schramm L.L. Preparation, inhibition, and destruction of dispersions. In: Schramm L.L. (Ed). Emulsions, foams, and suspensions: fundamentals and applications (2005), Weinheim, Wiley-VCH 201-223
21. Anonymous. Foam. Facts & Comparisons 4.0 [monograph on the Internet]. St. Louis: Wolters Kluwer Health. Available from http://www.factsandcomparisons.com/. [Accessed 26 January 2009].
22. Wilkinson A. The manufacture of metered dose inhalers. In: Purewell T.S., and Grant D.J.W. (Eds). Metered dose inhaler technology (1998), CRC Press LLC, Boca Raton (Fla) 69-117
23. Sanders P. Homogeneous systems and their properties. In: Sanders P. (Ed). Handbook of aerosol technology. 2nd ed. (1979), Van Nostrand Reinhold, New York 11-221
24. Sciarra J.J., and Cutie A.J. Aerosol suspensions and emulsions. In: Lieberman H.A., Rieger M.M., and Banker G.S. (Eds). Pharmaceutical dosage forms: disperse systems. 2nd ed. (1996), Dekker, New York 319-355
25. Ozone Secretariat, United Nations Environment Programme (UNEP). Summary of control measures under the Montreal Protocol. In: Ozone Secretarit, and UNEP (Eds). Handbook for the Montreal Protocol on Substances that Deplete the Ozone Layer. 7th ed. (2006), Secretariat of the Vienna Convention for the Protection of the Ozone Layer and the Montreal Protocol on Substances that Deplete the Ozone Layer, Nairobi, Kenya 27-40
26. McDonald K.J., and Martin G.P. Transition to CFC-free metered dose inhalers-into the new millennium. Int J Pharm 201 (2000) 89-107
27. Jones S.A., Martin G.P., and Brown M.B. High-pressure aerosol suspensions-a novel laser diffraction particle sizing system for hydrofluoroalkane pressurised metered dose inhalers. Int J Pharm 302 (2005) 154-165
28. Selvam P., Peguin R.P.S., Chokshi U., and da Rocha S.R.P. Surfactant design for the 1,1,1,2-tetrafluoroethane-water interface: ab initio calculations and in situ high-pressure tensiometry. Langmuir 22 (2006) 8675-8683
29. Peguin R.P.S., Selvam P., and da Rocha S.R.P. Microscopic and thermodynamic properties of the HFA134a-water interface: atomistic computer simulations and tensiometry under pressure. Langmuir 22 (2006) 8826-8830
30. Chokshi U., Selvam P., Porcar L., and da Rocha S.R.P. Reverse aqueous emulsions and microemulsions in HFA227 propellant stabilized by non-ionic ethoxylated amphiphiles. Int J Pharm 369 (2009) 176-184
31. Langevin D. Aqueous foams: a field of investigation at the frontier between chemistry and physics. Chemphyschem 9 (2008) 510-522
32. Stone H.A., Koehler S.A., Hilgenfeldt S., and Durand M. Perspectives on foam drainage and the influence of interfacial rheology. J Phys Condens Matter 15 (2003) S283-S290
33. Weaire D., and Hutzler S. Foam collapse. In: Weaire D., and Hutzler S. (Eds). The physics of foams (2001), Oxford University Press, Oxford 144-150
34. Pugh R.J. Foaming, foam films, antifoaming and defoaming. Adv Colloid Interface Sci 64 (1996) 67-142
35. Tan S.N., Fornasiero D., Sedev R., and Ralston J. The role of surfactant structure on foam behaviour. Colloids Surf A Physicochem Eng Asp 263 (2005) 233-238
36. Menon A., Prabhu C.S., Haridas M., Bellare J.R., and Mohan T.R.R. In situ formation and imaging of cellular alumina in a cryo-SEM environment. J Mater Sci Lett 16 (1997) 1506-1508
37. Sanders P. Emulsions, foams, and suspensions. In: Sanders P. (Ed). Handbook of aerosol technology. 2nd ed. (1979), Van Nostrand Reinhold, New York 305-309
38. Abram AZ, Hunt BT (inventors); Stiefel Research Australia, Pty Ltd. (Rowville, AU) (assignee). Pharmaceutical foam. United States patent US 7374747. 20 May 2008.
39. Weaire D., and Hutzler S. Imaging and probing foam structure. In: Weaire D., and Hutzler S. (Eds). The physics of foams (2001), Oxford University Press, Oxford 56-75
40. Kealy T., Abram A., Hunt B., and Buchta R. The rheological properties of pharmaceutical foam: implications for use. Int J Pharm 355 (2008) 67-80
41. Eini M, Tamarkin D (inventors); Foamix Ltd. (Ness Zion, IL) (assignee). Pharmaceutical and cosmetic carrier and composition for topical application. United States patent US 6994863. 7 Feb 2006.
42. Ricciatti-Sibbald D., and Sibbald R.G. Dermatologic vehicles. Clin Dermatol 7 (1989) 11-24
43. Housman T.S., Mellen B.G., Rapp S.R., Fleischer A.B., and Feldman S.R. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 70 (2002) 327-332
44. Gottlieb A.B., Ford R.O., and Spellman M.C. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 7 (2003) 185-192
45. Wai-Chiu So T, Deo PP, Tait RJ (inventors); Connetics Australia Pty Ltd. (Victoria, AU) (assignee). Pharmaceutical composition. United States patent US 6946120. 20 Sep 2005.
46. Tamarkin D, Friedman D, Eini M, Berman T, Schuz D, et al. (inventors); Foamix Ltd. (Ness Lion, IL) (assignee). Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof. United States patent US 20080069779. 20 Mar 2008.
47. Zarif L, Mallard C (inventors); Galderma S.A. (Cham, CH) (assignee). Topical foam/mousse compositions for treating psoriasis. United States patent US 20050281755. 22 Dec 2005.
48. Hirsh J, Willis II JC, Hirsh M (inventors); Pabst Patent Group LLP (Atlanta, GA, US) (assignee). Topical aerosol foams. United States patent US 20060188449. 24 Aug 2006.
49. Tamarkin D, Friedman D, Eini M, Besonov A, Danziger J, Schuz D, et al. (inventors); Foamix Ltd. (Ness Zion, IL) (assignee). Oleaginous pharmaceutical and cosmetic foam. United States patent US 20070292461. 20 Dec 2007.
50. Tamarkin D, Friedman D, Besonov A (inventors); (Ness Zion, IL) (assignee). Saccharide foamable compositions. United States patent US 20060275221. 7 Dec 2006.
51. Friedman D, Tamarkin D, Feiman N, Schuz D, Berman T. (inventors); Foamix Ltd. (Ness Zion, IL) (assignee). Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof. United States patent US 20080152596. 26 Jun 2008.
52. Tamarkin D, Friedman D, Eini M, Besonov A (inventors); Foamix Ltd. (Ness Zion, IL) (assignee). Cosmetic and pharmaceutical foam with solid matter. United States patent US 20050186147. 25 Aug 2005.
53. Ho Y (inventor); Connetics Corporation (Palo Alto, CA, US) (assignee). Aerosol system having lockable cap. United States patent US 7222754. 29 May 2007.
54. Barranco S, Leone P (inventors); Valois S.A.S (Le Neubourg, FR) (assignee). Valve gasket. United States patent US 7396019. 8 Jul 2008.
55. Trumbore MW, Gurge RM, Hirsh JC (inventors); Collegium Pharmaceutical, Inc. (Cumberland, RI, US) (assignee). Topical pharmaceutical foam composition. United States patent US 20070154402. 5 Jul 2007.
56. Tamarkin D, Friedman D, Eini M (inventors); Foamix Ltd. (Ness Zion, IL) (assignee). Foam incorporating eutetic mixture. United States patent US 20050075407. 7 Apr 2005.
57. Konis Y, Kalay A (inventors); Kamedis Ltd. (Rehovot, IL) (assignee). Cosmetic and pharmaceutical foam carrier. United States patent US 20070224143. 27 Sep 2007.
58. Huggins JK, Houlden RJ (inventors); Connetics Australia Pty Ltd. (Rowville, AU) (assignee). Film foaming hydroalcoholic foam. United States patent US 20060233727. 19 Oct 2006.
59. Lorant R (inventors); L'Oreal S. A. (Paris, FR) (assignee). Pressurized device comprising an ultrafine foaming oil-in-water emulsion and use of this emulsion in cleansing and care of skin. United States patent US 6620855. 16 Sep 2003.
60. Tamarkin D, Eini M, Friedman D, Zlatkis E, Schuz D, Berman T (inventors); Foamix Ltd. (Ness Zion, IL) (assignee). Sensation modifying topical composition foam. United States patent US 20080253973. 16 Oct 2008.
61. Jones JI, Baker AR, Halls NG, Watmough P, Marriott P (inventors); Medeva Europe PLC (London, GB) (assignee). Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition. United States patent US 6126920. 3 Oct 2000.
62. Abram AZ, Goldstein L (inventors); Stiefel Research Australia, Pty Ltd. (Rowville, AU) (assignee). Fatty acid pharmaceutical foam. World patent WO 2008/008397. 17 Jan 2008.
63. Abram AZ (inventor); Connetics Australia Pty Ltd. (Rowville, AU) (assignee). Mousse composition. United States patent US 7029659. 18 Apr 2006.
64. Abram AZ (inventor); Connetics Australia Pty Ltd. (Rowville, AU) (assignee). Mousse composition. United States patent US 6730288. 4 May 2004.
65. Gupta A.K., Gover M.D., and Abramovits W. EVOCLIN (clindamycin phosphate foam, 1%). Skinmed 4 (2005) 96-97
66. Barry B.W. Drug delivery routes in skin: a novel approach. Adv Drug Deliv Rev 54 (2002) S31-S40
67. Ryman-Rasmussen J.P., Riviere J.E., and Monteiro-Riviere N.A. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicol Sci 91 (2006) 159-165
68. Baroli B., Ennas M.G., Loffredo F., Isola M., Pinna R., Lopez-Quintela M.A., et al. Penetration of metallic nanoparticles in human full-thickness skin. J Invest Dermatol 127 (2007) 1701-1712
69. Luengo J., Weiss B., Schneider M., Ehlers A., Stracke F., Konig K., et al. Influence of nanoencapsulation on human skin transport of flufenamic acid. Skin Pharmacol Physiol 19 (2006) 190-197
70. Cross S.E., Innes B., Roberts M.S., Tsuzuki T., Robertson T.A., McCormick P., et al. Human skin penetration of sunscreen nanoparticles: in-vitro assessment of a novel micronized zinc oxide formulation. Skin Pharmacol Physiol 20 (2007) 148-154
71. Pflucker F., Hohenberg H., Holzle E., Will T., Pfeiffer S., Wepf R., et al. The outermost stratum corneum layer is an effective barrier against dermal uptake of topically applied micronized titanium dioxide. Int J Cosmet Sci 21 (1999) 399-411
72. Schulz J., Hohenberg H., Pflücker F., Gärtner E., Will T., Pfeiffer S., et al. Distribution of sunscreens on skin. Adv Drug Deliv Rev 54 (2002) S157-S163
73. Muller B., and Kreuter J. Enhanced transport of nanoparticle associated drugs through natural and artificial membranes-a general phenomenon?. Int J Pharm 178 (1999) 23-32
74. Jenning V., Gysler A., Schafer-Korting M., and Gohla S.H. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 49 (2000) 211-218
75. Shah K.A., Date A.A., Joshi M.D., and Patravale V.B. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm 345 (2007) 163-171
76. Mei Z.N., Chen H.B., Weng T., Yang Y.J., and Yang X.L. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 56 (2003) 189-196
77. Wissing S.A., and Muller R.H. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release 81 (2002) 225-233
78. Olvera-Martinez B.I., Cazares-Delgadillo J., Calderilla-Faardo S.B., Villalobos-Garcia R., Ganem-Quintanar A., and Quintanar-Guerrero D. Preparation of polymeric nanocapsules containing octyl methoxycinnamate by the emulsification-diffusion technique: penetration across the stratum corneum. J Pharm Sci 94 (2005) 1552-1559
79. Souto E.B., Wissing S.A., Barbosa C.M., and Muller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 278 (2004) 71-77
80. Chen H.B., Chang X.L., Du D.R., Liu W., Liu J., Weng T., et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 110 (2006) 296-306
81. Borgia S.L., Regehly M., Sivaramakrishnan R., Mehnert W., Korting H.C., Danker K., et al. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release 110 (2005) 151-163
82. Alves M.P., Scarrone A.L., Santos M., Pohlmann A.R., and Guterres S.S. Human skin penetration and distribution of nimesulide from hydrophilic gels containing nanocarriers. Int J Pharm 341 (2007) 215-220
83. Liu J., Hu W., Chen H., Ni Q., Xu H., and Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm 328 (2007) 191-195
84. Lademann J., Richter H., Teichmann A., Otberg N., Blume-Peytavi U., Luengo J., et al. Nanoparticles-an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm 66 (2007) 159-164
85. Zhao Y., Brown M.B., and Jones S.A. The topical delivery of benzoyl peroxide using elegant dynamic hydrofluoroalkane foams. J Pharm Sci (2009) (in press)
86. Zhao Y., Brown M.B., and Jones S.A. The effects of particle properties on nanoparticle drug retention and release in dynamic minoxidil foams. Int J Pharm (2009) (in press)